Neurogene
Alexis Cattin-Roy, PhD has a diverse work experience in the field of research. Currently, they are working at Neurogene Inc. as a Scientist, starting in August 2021. Prior to that, they worked at KBI Biopharma as a Cell Therapy Associate II from June 2021 to August 2021. They also worked as a Graduate Research Associate at the University of Missouri-Columbia, School of Medicine from August 2015 to May 2021. Additionally, they served as a Teaching Assistant at the University of Missouri-Columbia from May 2013 to August 2016 and as a Research Assistant from September 2013 to May 2015.
Alexis Cattin-Roy, PhD, pursued a Bachelor's degree in Animal Sciences from the University of Missouri-Columbia from 2011 to 2015. Following this, they continued their education at the same institution and obtained a Doctor of Philosophy (Ph.D.) in Immunology between 2015 and 2021.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.